Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
46 hedge funds and large institutions have $13.3M invested in Cidara Therapeutics in 2022 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 6 closing their positions.
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
5% more funds holding
Funds holding: 44 → 46 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.25% less ownership
Funds ownership: 2.22% → 1.97% (-0.25%)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
47% less capital invested
Capital invested by funds: $25.2M → $13.3M (-$11.9M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
US Bancorp
Minneapolis,
Minnesota
|
+$162K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$35.4K |
| 3 |
DMKJ
David M. Knott Jr
|
+$34.7K |
| 4 |
Jane Street
New York
|
+$25.1K |
| 5 |
JWM
Jeppson Wealth Management
Manhattan Beach,
California
|
+$23K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$1.41M |
| 2 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$307K |
| 3 |
Renaissance Technologies
New York
|
-$174K |
| 4 |
ACM
Alethea Capital Management
Mercer Island,
Washington
|
-$162K |
| 5 |
BlackRock
New York
|
-$91K |
CDTX Hedge Fund Activity: Q2 2022 in Review
46 of the 5,958 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q2 2022, worth a combined $13.3M — down 47% from $25.2M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CDTX positions and 6 closed out — a net gain of 2 holders — while 10 added to existing stakes and 12 trimmed.
The largest buyer was US Bancorp, opening a new position worth an estimated $162K. The largest seller was Stonepine Capital Management, cutting an estimated $1.41M.
- 46 institutional investors held Cidara Therapeutics (CDTX) as of Q2 2022, up from 44 in Q1 2022.
- Funds reported $13.3M of Cidara Therapeutics stock for Q2 2022, down 47% quarter-over-quarter.
- 8 funds opened new Cidara Therapeutics positions in Q2 2022 and 6 closed out, a net change of +2 holders.
- The largest Cidara Therapeutics buyer in Q2 2022 was US Bancorp, an estimated $162K added.
- The largest Cidara Therapeutics seller in Q2 2022 was Stonepine Capital Management, an estimated $1.41M sold.
Based on aggregated 13F filings for Q2 2022.